BRPI0410470A - uso de uma eritropoietina ou de uma citocina protetora de tecido e método para proteger ou manter a viabilidade de uma célula, tecido ou órgão de mamìfero respondente - Google Patents

uso de uma eritropoietina ou de uma citocina protetora de tecido e método para proteger ou manter a viabilidade de uma célula, tecido ou órgão de mamìfero respondente

Info

Publication number
BRPI0410470A
BRPI0410470A BRPI0410470-6A BRPI0410470A BRPI0410470A BR PI0410470 A BRPI0410470 A BR PI0410470A BR PI0410470 A BRPI0410470 A BR PI0410470A BR PI0410470 A BRPI0410470 A BR PI0410470A
Authority
BR
Brazil
Prior art keywords
tissue
protecting
organ
erythropoietin
cytokine
Prior art date
Application number
BRPI0410470-6A
Other languages
English (en)
Inventor
Anthony Cerami
Michael Brines
Thomas Coleman
Original Assignee
Kenneth S Warren Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth S Warren Inst Inc filed Critical Kenneth S Warren Inst Inc
Publication of BRPI0410470A publication Critical patent/BRPI0410470A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)

Abstract

"USO DE UMA ERITROPOIETINA OU DE UMA CITOCINA PROTETORA DE TECIDO E MéTODO PARA PROTEGER OU MANTER A VIABILIDADE DE UMA CéLULA, TECIDO OU ORGãO DE MAMìFERO RESPONDENTE". Métodos e usos são apresentados para uma composição farmacêutica com uma eritropoietina ou citocina protetora de tecido para proteger ou restaurar a função a uma célula, tecido, órgão ou função de parte do corpo respondentes ou viabilidade em mamíferos quando administrados fora da janela terapêutica de terapêuticas previamente aprovadas.
BRPI0410470-6A 2003-05-19 2004-05-19 uso de uma eritropoietina ou de uma citocina protetora de tecido e método para proteger ou manter a viabilidade de uma célula, tecido ou órgão de mamìfero respondente BRPI0410470A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47166103P 2003-05-19 2003-05-19
PCT/US2004/015733 WO2004112693A2 (en) 2003-05-19 2004-05-19 Tissue protective cytokines with an extended therapeutic window

Publications (1)

Publication Number Publication Date
BRPI0410470A true BRPI0410470A (pt) 2006-06-20

Family

ID=33539032

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410470-6A BRPI0410470A (pt) 2003-05-19 2004-05-19 uso de uma eritropoietina ou de uma citocina protetora de tecido e método para proteger ou manter a viabilidade de uma célula, tecido ou órgão de mamìfero respondente

Country Status (13)

Country Link
US (1) US20090258821A1 (pt)
EP (1) EP1633305A2 (pt)
JP (1) JP2007505159A (pt)
KR (1) KR20060013547A (pt)
CN (1) CN1946416A (pt)
BR (1) BRPI0410470A (pt)
CA (1) CA2526096A1 (pt)
EA (1) EA200501828A1 (pt)
IL (1) IL172035A0 (pt)
IS (1) IS8156A (pt)
MX (1) MXPA05012515A (pt)
NO (1) NO20056000L (pt)
WO (1) WO2004112693A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EP1633383A4 (en) * 2003-03-27 2008-05-21 Janssen Pharmaceutica Nv USE OF ERYTHROPOIETIN FOR RE-ESTABLISHMENT FOLLOWING A CEREBRAL ISCHEMIC ACCIDENT
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
EP1771190A4 (en) * 2004-07-02 2009-07-22 Kenneth S Warren Inst Inc METHOD FOR THE PRODUCTION OF COMPLETELY CARBAMYLATED ERYTHROPOIETIN
EA011586B1 (ru) * 2004-07-07 2009-04-28 Х. Лундбекк А/С Новый карбамилированный еро и способ его получения
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
TW201129374A (en) * 2009-10-26 2011-09-01 Lundbeck & Co As H Use of carbamylated erythropoietin for the treatment of Friedreich's ataxia
US9956265B2 (en) * 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
DK2723363T3 (en) 2011-06-24 2018-10-15 Nono Inc COMBINATION THERAPY AGAINST CREAM
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
US10695402B2 (en) * 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
RU2762892C1 (ru) * 2021-02-18 2021-12-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляторных нарушений сетчатки асиалированным эритропоэтином

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
EP1633383A4 (en) * 2003-03-27 2008-05-21 Janssen Pharmaceutica Nv USE OF ERYTHROPOIETIN FOR RE-ESTABLISHMENT FOLLOWING A CEREBRAL ISCHEMIC ACCIDENT

Also Published As

Publication number Publication date
EA200501828A1 (ru) 2006-08-25
IL172035A0 (en) 2009-02-11
JP2007505159A (ja) 2007-03-08
EP1633305A2 (en) 2006-03-15
KR20060013547A (ko) 2006-02-10
NO20056000L (no) 2006-02-20
US20090258821A1 (en) 2009-10-15
IS8156A (is) 2005-11-29
MXPA05012515A (es) 2006-05-25
WO2004112693A2 (en) 2004-12-29
CN1946416A (zh) 2007-04-11
WO2004112693A3 (en) 2006-06-29
CA2526096A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
BRPI0410470A (pt) uso de uma eritropoietina ou de uma citocina protetora de tecido e método para proteger ou manter a viabilidade de uma célula, tecido ou órgão de mamìfero respondente
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
NO332893B1 (no) Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
BR0214650A (pt) Imunocitoquinas com seletividade modulada
BR0311939A (pt) composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico
DK1021204T3 (da) Bioadhæsive præparater og fremgangsmåder til topisk administration af aktive midler
BR0312506A (pt) Composições transdérmicas de toxina botulìnica
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
BR0312395A (pt) citocina protetora de tecido recombinante de muteìna, célula de mamìfero responsiva à citocina protetora de tecido recombinante, molécula de ácido nucleico isolada, vetor, vetor de expressão, célula geneticamente engenheirada, célula, composição farmacêutica, método para proteger, manter ou realçar a viabilidade de uma célula, tecido ou órgão isolados de um corpo de mamìfero, uso de uma citocina protetora de tecido recombinante, método para facilitar a transcitose de uma molécula através de uma barreira de célula endotelial em um mamìfero, e, composição para transportar uma molécula por intermédio da transcitose através de uma barreira de célula endotelial
BRPI0514293A (pt) sais de dicetopiperazina, sais de dicetomorfolina ou sais de dicetodioxano para administração de droga
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
WO2003028758A1 (fr) Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
NO975192D0 (no) Bicykliske aromatiske forbindelser
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
AU1727797A (en) Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
BR0311866A (pt) Composições de saponinas ou sapogeninas para terapia de câncer
ATE198467T1 (de) Diaromatische propynyl- oder dienylverbindungen
BR0009170A (pt) ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
BRPI0518619A2 (pt) mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica
FR2915397B1 (fr) Composition pharmaceutique et/ou cosmetique contenant des principes actifs activateurs de l'aconitase
NO20051261L (no) Morfin-6-glukuronidsalt
AU2003215878A1 (en) Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
DE69717311D1 (de) Kosmetische, dermatologische und pharmazeutische anwendung eines terminalia catappa pflanzenextrakts
ATE517121T1 (de) Integrin-heterodimer und eine alpha-untereinheit davon

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.